Author Correction: CD98hc is a target for brain delivery of biotherapeutics

Nat Commun. 2023 Sep 7;14(1):5516. doi: 10.1038/s41467-023-41355-x.

Authors

Kylie S Chew^#¹, Robert C Wells^#¹, Arash Moshkforoush¹, Darren Chan¹, Kendra J Lechtenberg¹, Hai L Tran¹, Johann Chow¹, Do Jin Kim¹, Yaneth Robles-Colmenares¹, Devendra B Srivastava¹, Raymond K Tong¹, Mabel Tong¹, Kaitlin Xa¹, Alexander Yang¹, Yinhan Zhou¹, Padma Akkapeddi¹, Lakshman Annamalai¹, Kaja Bajc^{2

3}, Marie Blanchette^{2

3}, Gerald Maxwell Cherf¹, Timothy K Earr¹, Audrey Gill¹, David Huynh¹, David Joy¹, Kristen N Knight¹, Diana Lac¹, Amy Wing-Sze Leung¹, Katrina W Lexa¹, Nicholas P D Liau¹, Isabel Becerra¹, Mario Malfavon^{2

3}, Joseph McInnes¹, Hoang N Nguyen¹, Edwin I Lozano¹, Michelle E Pizzo¹, Elysia Roche¹, Patricia Sacayon¹, Meredith E K Calvert¹, Richard Daneman^{2

3}, Mark S Dennis¹, Joseph Duque¹, Kapil Gadkar¹, Joseph W Lewcock¹, Cathal S Mahon¹, René Meisner¹, Hilda Solanoy¹, Robert G Thorne^{1

4}, Ryan J Watts¹, Y Joy Yu Zuchero⁵, Mihalis S Kariolis⁶

Affiliations

¹ Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
² Department of Pharmacology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA.
³ Department of Neurosciences, University of California San Diego, 9500 Gilman Dr., La Jolla, CA, 92093, USA.
⁴ Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, USA.
⁵ Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. zuchero@dnli.com.
⁶ Denali Therapeutics, Inc., 161 Oyster Point Blvd., South San Francisco, CA, 94080, USA. kariolis@dnli.com.

^# Contributed equally.

No abstract available

Publication types

Published Erratum